Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Alx Oncology Holdings Inc (NASDAQ: ALXO) was $1.18 for the day, down -6.35% from the previous closing price of $1.26. In other words, the price has decreased by -$6.35 from its previous closing price. On the day, 0.82 million shares were traded. ALXO stock price reached its highest trading level at $1.35 during the session, while it also had its lowest trading level at $1.13.
Ratios:
Our analysis of ALXO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Jefferies on March 06, 2025, Upgraded its rating to Buy and sets its target price to $3 from $2 previously.
On December 19, 2024, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $12 to $2.
Stifel Downgraded its Buy to Hold on March 08, 2024, whereas the target price for the stock was revised from $10 to $14.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 17 ’25 when Lettmann Jason bought 71,163 shares for $1.08 per share. The transaction valued at 76,892 led to the insider holds 305,121 shares of the business.
Lettmann Jason bought 21,070 shares of ALXO for $22,461 on Sep 16 ’25. The CHIEF EXECUTIVE OFFICER now owns 233,958 shares after completing the transaction at $1.07 per share. On Aug 18 ’25, another insider, Shantharam Harish, who serves as the Chief Financial Officer of the company, bought 75,000 shares for $0.78 each. As a result, the insider paid 58,402 and bolstered with 75,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 63190336 and an Enterprise Value of 58338.
Stock Price History:
The Beta on a monthly basis for ALXO is 0.55, which has changed by -0.1310345 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ALXO has reached a high of $2.27, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is -20.92%, while the 200-Day Moving Average is calculated to be 29.74%.
Shares Statistics:
ALXO traded an average of 911.92K shares per day over the past three months and 320410 shares per day over the past ten days. A total of 53.51M shares are outstanding, with a floating share count of 37.50M. Insiders hold about 29.98% of the company’s shares, while institutions hold 41.22% stake in the company. Shares short for ALXO as of 1760486400 were 1860704 with a Short Ratio of 2.04, compared to 1757894400 on 1577840. Therefore, it implies a Short% of Shares Outstanding of 1860704 and a Short% of Float of 5.53.
Earnings Estimates
. The current rating of Alx Oncology Holdings Inc (ALXO) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.25 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.64 and -$1.86 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$2.64, with 2 analysts recommending between -$1.7 and -$3.58.
